Olivier Kosmider
YOU?
Author Swipe
View article: UBA1 Mutations Drive RIPK1-Mediated Cell Death and Monocyte Dysfunction in VEXAS Syndrome
UBA1 Mutations Drive RIPK1-Mediated Cell Death and Monocyte Dysfunction in VEXAS Syndrome Open
VEXAS syndrome is a severe adult-onset autoinflammatory disease caused by somatic mutations in UBA1 gene, disrupting cytoplasmic ubiquitin-activating enzyme E1 function in hematopoietic progenitors. The pathogenesis remains poorly understo…
View article: Comparative efficacy and safety of anakinra and canakinumab in patients with <scp>VEXAS</scp> syndrome – an international multicenter study
Comparative efficacy and safety of anakinra and canakinumab in patients with <span>VEXAS</span> syndrome – an international multicenter study Open
Objectives The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS syndrome. Methods This multicenter international study includes VEXAS patien…
View article: MDS BIOLOGY AND PATHOGENESIS - IMMUNE DEREGULATION / INFLAMMATION
MDS BIOLOGY AND PATHOGENESIS - IMMUNE DEREGULATION / INFLAMMATION Open
View article: Pro-inflammatory role of granzyme K producing bystander CD8<sup>+</sup> T cells in acute myeloid leukemia
Pro-inflammatory role of granzyme K producing bystander CD8<sup>+</sup> T cells in acute myeloid leukemia Open
Acute myeloid leukemia (AML) is a heterogeneous group of blood malignancies with a 5-year survival rate below 30%, highlighting the urgent need for more effective therapeutic strategies. T cell-based immunotherapies have demonstrated remar…
View article: Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX
Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX Open
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a severe monogenic disorder caused by somatic mutations in ubiquitin-like modifier activating enzyme 1 (UBA1), characterized by inflammation, cytopenias, and freq…
View article: Orchestration of human multi‐lineage hematopoietic cell development by humanized in vivo bone marrow models
Orchestration of human multi‐lineage hematopoietic cell development by humanized in vivo bone marrow models Open
Hematopoiesis develops in the bone marrow (BM) where multiple interactions regulate the differentiation and preservation of hematopoietic stem and progenitor cells (HSPCs). Immune‐deficient murine models have enabled the analysis of molecu…
View article: Implementation science in hemato‐oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)
Implementation science in hemato‐oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM) Open
View article: Very long-term remission with azacitidine in VEXAS syndrome
Very long-term remission with azacitidine in VEXAS syndrome Open
Not available.
View article: High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine
High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine Open
Contains fulltext : 314896.pdf (Publisher’s version ) (Open Access)
View article: Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower‐risk myelodysplastic syndromes
Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower‐risk myelodysplastic syndromes Open
Lower risk (LR) myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem and progenitor disorders caused by the accumulation of somatic mutations in various genes including epigenetic regulators that may produce convergent DNA …
View article: Nonischemic Cardiac Manifestations in VEXAS Syndrome
Nonischemic Cardiac Manifestations in VEXAS Syndrome Open
This case series reports on the clinical presentation, laboratory findings, imaging characteristics, treatments, and outcomes of nonischemic cardiac manifestations in patients with VEXAS syndrome with confirmed pathogenic UBA1 alterations.
View article: Erratum for Barbosa Bomfim et al., “CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients”
Erratum for Barbosa Bomfim et al., “CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients” Open
View article: VEXAS anemia is a mosaic erythroblastopenia
VEXAS anemia is a mosaic erythroblastopenia Open
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a recently discovered autoinflammatory disorder linked to somatic mutations in the UBA1 gene, resulting in a profound cytoplasm-restricted defect in ubiquitylation. The di…
View article: A Clinicopathological Description of Kidney Features in VEXAS Syndrome
A Clinicopathological Description of Kidney Features in VEXAS Syndrome Open
View article: Comparison of prognostic scores according to <scp>WHO</scp> classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin
Comparison of prognostic scores according to <span>WHO</span> classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin Open
Advanced systemic mastocytosis (AdvSM) encompasses heterogeneous mastocytosis subtypes and is associated with poor outcomes. Although midostaurin was the first tyrosine kinase inhibitor to be approved for AdvSM patients, long‐lasting respo…
View article: Data from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Data from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
While transcription factor C/AAT-enhancer binding protein a (C/EBPa) is critical for normal and leukemic differentiation, its role on cell and metabolic homeostasis is largely unknown in cancer. Here, multi-omics analyses uncovered a coord…
View article: Supplementary Table S4 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Table S4 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Table S4: GSEA results in FLT3-ITD PDX AML cells ex vivo-treated with QUIZ or Veh.
View article: Supplementary Table S13 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Table S13 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Table S13: lipidomic results by lipid species in dox-inducible and constitutives shRNAs and siRNA CTL/CEBPA, empty vector/CEBPA-OE and vehicle/QUIZ conditions in MOLM-14 cells
View article: Supplementary Table S6 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Table S6 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Table S6: Proteomic analysis of FLT3-ITD AML cell lines treated with vehicle or QUIZ
View article: Supplementary Table S12 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Table S12 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Table S12: gene signatures used to analyze RNA-seq data from patients with AML before/after GILT
View article: Supplementary Table S9 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Table S9 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Table S9: CEBPA_UP signature
View article: Supplementary Information v.2 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Information v.2 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Supplementary materials and methods
View article: Supplementary Table S12 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Table S12 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Table S12: gene signatures used to analyze RNA-seq data from patients with AML before/after GILT
View article: Supplementary Table S6 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Table S6 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Table S6: Proteomic analysis of FLT3-ITD AML cell lines treated with vehicle or QUIZ
View article: Supplementary Table S2 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Table S2 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Table S2: EnrichR analysis of FLT3 gene signatures
View article: Supplementary Table S14 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Table S14 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Table S14: PUFA/MUFA ratios in phospholipids
View article: Supplementary Figures S1-S22 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Figures S1-S22 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Supplemental figures S1-S22: Supplementary Figure S1 shows lipid metabolism dependency in FLT3-mutant AML, Supplementary Figure S2 shows anti-leukemic activity of GILT across a panel of AML PDX, Supplementary Figure S3 shows mechanisms of …
View article: Supplementary Table S1 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Table S1 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Table S1: Transcriptome analysis of FLT3-ITD cell lines after FLT3 inhbition
View article: Supplementary Information v.2 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Information v.2 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Supplementary materials and methods
View article: Supplementary Table S5 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia
Supplementary Table S5 from C/EBPa confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress-induced ferroptosis in FLT3-mutant leukemia Open
Table S5: GSEA results in FLT3-ITD PDX AML cells in vivo-treated with GILT or Veh.